Dermatology Times 2025 Year in Review: Rosacea

Throughout 2025, rosacea remained a key area of focus in dermatology, reflecting both its high prevalence and the ongoing challenges associated with managing a chronic, heterogeneous inflammatory condition. Over the past year, Dermatology Times reported on a range of developments shaping rosacea care, from FDA approvals and late-stage clinical trial results to emerging research on microbiome involvement, barrier dysfunction, and energy-based therapies.

Updates in the Clinical Landscape

From the FDA approval and launch of dual-release minocycline to broader reviews of pediatric rosacea and global psychosocial data, these milestones underscored both therapeutic momentum and the continued need for individualized, long-term disease management strategies in patients with rosacea.

DFD-29: The Journey to FDA Approval and a New Era in Rosacea Management

DFD-29, FDA-approved in 2024, revolutionizes rosacea management by addressing both erythema and inflammatory lesions with a novel extended-release formulation.

Journey Medical Publishes Full Phase 3 Trial Results for DFD-29

The findings of the MVOR-1 and MVOR-2 studies are published in JAMA Dermatology, supporting the rosacea drug’s recent FDA approval.

Journey Medical Launches Emrosi, a Dual-Release Minocycline for Rosacea

The lowest-dose oral minocycline for rosacea is now available by prescription following FDA approval in November 2024.

An Up-to-Date Review of Rosacea in Childhood and Adolescence

Researchers behind a recent review shared expert insights, treatment guidelines, and differential diagnosis techniques for pediatric rosacea.

Rosacea: Progress, Challenges, and the Road Ahead

Experts explore how rosacea research is evolving, with new treatments, gaps in care, and a push for more inclusive, targeted approaches.

Unveiling the Psychosocial Impact and Lifestyle Factors Associated with Rosacea in China

Discover the latest insights on laser and energy-based treatments for rosacea, highlighting the effectiveness of radiofrequency microneedling and combination therapies.

Expert Perspectives

Expert interviews from 2025 offered insight into the underlying drivers of rosacea and practical approaches to care, blending emerging science with everyday clinical decision-making. Discussions explored the role of the microbiome, evidence-based skin care selection, and the lived experience of rosacea.

Choosing the Correct Skin Care for Rosacea with skinbetter science and Zoe Diana Draelos, MD

For Rosacea Awareness Month, Zoe Diana Draelos, MD, spoke to Dermatology Times about skinbetter’s Mystro Active Balance Serum and its NRS Seal of Acceptance.

Treating Rosacea and Other Concerns with Generative Skin’s Ingredient Library

As a patient with rosacea herself, Anastasia Georgievskaya highlights the innovation of Generative Skin in patient education.

Beyond the Myths: Expert Data Updates on Acne and Rosacea Management

Discover key insights from Maui Derm NP+PA Fall 2025 on acne and rosacea treatments, featuring expert strategies from Hilary Baldwin, MD.

Emerging Research and Investigational Approaches

New evidence featured throughout the year reflected growing interest in adjunctive and procedural therapies for rosacea, particularly for persistent erythema and barrier dysfunction. Studies examining PRP, topical and injectable therapies, mesotherapy, and energy-based devices highlighted an expanding treatment toolbox aimed at improving outcomes, patient satisfaction, and quality of life

PRP Injection is an Effective Standalone and Combination Therapy for Rosacea

Symptoms of rosacea and dependence on oral medication were reduced in all 5 case studies.

New Study Supports SSA for Rosacea Treatment

Patients receiving SSA treatments showed significant improvements after just 2 sessions, supporting its rapid efficacy.

Oxymetazoline 1% Cream Reduces Erythema in Patients with Rosacea

The product was safe and effective after 4 weeks of topical use, specifically on patients with darker skin types.

Compound Heparin Sodium Allantoin Gel Can Treat Rosacea and Improve Skin Barrier

Improvements in hydration, erythema, itching, and burning were observed after 12 weeks of treatment for papulopustular rosacea.

Hyaluronic–Succinic Mesotherapy Cuts Rosacea Redness by 80 %

Discover how mesotherapy with hyaluronic and succinic acids significantly improves rosacea symptoms, offering a cost-effective adjunct therapy option.

New Analysis Finds Radiofrequency Microneedling Superior for Rosacea Erythema and Patient Satisfaction

Discover the latest insights on laser and energy-based treatments for rosacea, highlighting the effectiveness of radiofrequency microneedling and combination therapies.